Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation.
暂无分享,去创建一个
Alan L. Clark | A. Kaye | R. Schroeder | Brook Girma | Sonja A. Gennuso | S. Ahmadzadeh | Sahar Shekoohi | D. McGregor | B. Tate | Bretton Urban | Shahab Ahmadzadeh
[1] H. Schiöth,et al. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials , 2022, Frontiers in Pharmacology.
[2] T. Ikuta,et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis , 2022, Molecular Psychiatry.
[3] C. S. Hendershot,et al. Effects of varenicline and bupropion on laboratory smoking outcomes: Meta‐analysis of randomized, placebo‐controlled human laboratory studies , 2022, Addiction biology.
[4] M. Fava,et al. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). , 2022, The Journal of clinical psychiatry.
[5] D. Iosifescu,et al. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. , 2022, The American journal of psychiatry.
[6] Jennifer A. Minnix,et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial , 2022, Depression and anxiety.
[7] Kehu Yang,et al. The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. , 2022, Addictive behaviors.
[8] T. Bschor,et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. , 2022, JAMA psychiatry.
[9] N. Rigotti,et al. Treatment of Tobacco Smoking: A Review. , 2022, JAMA.
[10] Liang-Jen Wang,et al. The comparative effectiveness of antidepressants for youths with major depressive disorder: a nationwide population-based study in Taiwan , 2022, Therapeutic advances in chronic disease.
[11] Liang-Jen Wang,et al. Comparative Effectiveness of Antidepressants on Geriatric Depression: Real-world Evidence from a Population-based Study. , 2021, Journal of affective disorders.
[12] B. Hutton,et al. Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review. , 2021, Clinical breast cancer.
[13] R. Goldman,et al. Bupropion for smoking cessation in adolescents , 2021, Canadian Family Physician Médecin de famille canadien.
[14] D. McCabe,et al. The Timing of Clinical Effects of Bupropion Misuse Via Insufflation Reported to a Regional Poison Center. , 2021, The Journal of emergency medicine.
[15] M. Amore,et al. Antidepressant Drugs Effects on Blood Pressure , 2021, Frontiers in Cardiovascular Medicine.
[16] C. Masimirembwa,et al. CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations—Implication for Drug Safety, Dosing, and Individualized Therapy , 2021, Frontiers in Genetics.
[17] K. Leander,et al. CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study , 2021, Scientific Reports.
[18] Jillian T Henderson,et al. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2021, JAMA.
[19] H. Kranzler,et al. Placebo-Controlled Trial of Bupropion for Smoking Cessation in Pregnant Women. , 2021, American journal of obstetrics & gynecology MFM.
[20] J. Son,et al. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs , 2020, Diabetes & metabolism journal.
[21] M. Pirmohamed,et al. A Review of the Important Role of CYP2D6 in Pharmacogenomics , 2020, Genes.
[22] R. Sarzani,et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice , 2020, High Blood Pressure & Cardiovascular Prevention.
[23] Jaekyu Shin,et al. Combining Antidepressants with β‐Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction , 2020, Pharmacotherapy.
[24] M. Picciotto,et al. Mechanisms of Nicotine Addiction. , 2020, Cold Spring Harbor perspectives in medicine.
[25] M. Abesamis,et al. Serotonin toxicity from isolated bupropion overdoses , 2020, Clinical toxicology.
[26] R. Pandey,et al. Nicotine Addiction: Neurobiology and Mechanism , 2020, Journal of pharmacopuncture.
[27] Bupropion , 2020, Reactions Weekly.
[28] Xiufeng Xu,et al. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. , 2019, Journal of affective disorders.
[29] Shuyue Xia,et al. Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. , 2019, Comprehensive psychiatry.
[30] R. Dinis-Oliveira,et al. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects , 2019, Drug metabolism reviews.
[31] F. Shokraneh,et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis , 2018, The lancet. Psychiatry.
[32] Y. Kanbay,et al. Treatment adherence and short-term outcomes of smoking cessation outpatient clinic patients , 2018, Tobacco induced diseases.
[33] R. Goodwin,et al. Socioeconomic Disparities in Smoking Among U.S. Adults With Depression, 2005-2014. , 2018, American journal of preventive medicine.
[34] I. Gräff,et al. Adverse Drug Reactions (ADR) and Emergencies. , 2018, Deutsches Arzteblatt international.
[35] G. Russo,et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study , 2018, Front. Pharmacol..
[36] Z. Xi,et al. Discovery and development of varenicline for smoking cessation , 2018, Expert opinion on drug discovery.
[37] T. Patel,et al. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis , 2018, European Journal of Clinical Pharmacology.
[38] Jie Gao,et al. An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments , 2016, Molecular Neurobiology.
[39] W. Van den Noortgate,et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. , 2017, The Cochrane database of systematic reviews.
[40] D. Moher,et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials , 2017, PloS one.
[41] G. Harrington,et al. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers , 2017, The AAPS Journal.
[42] Q. Ng. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. , 2017, Journal of child and adolescent psychopharmacology.
[43] R. Glennon,et al. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. , 2017, ACS chemical neuroscience.
[44] Gina L Stassinos,et al. Bupropion “Abuse” Reported to US Poison Centers , 2016, Journal of addiction medicine.
[45] W. L. Nelson,et al. Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. , 2016, ACS medicinal chemistry letters.
[46] T. Lancaster,et al. Nicotine receptor partial agonists for smoking cessation. , 2016, The Cochrane database of systematic reviews.
[47] D. Tracy,et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant , 2016, Therapeutic advances in psychopharmacology.
[48] K. Evoy,et al. Combination bupropion SR and varenicline for smoking cessation: a systematic review , 2016, The American journal of drug and alcohol abuse.
[49] I. Locatelli,et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. , 2015, Journal of affective disorders.
[50] P. Shahabi,et al. Effects of Acute Intracerebroventricular Microinfusions of Bupropion on Background Spike Activity of Locus Coeruleus Neurons in Rats , 2014, Neurophysiology.
[51] P. Asherson,et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials , 2014, Journal of psychopharmacology.
[52] J. Calabrese,et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. , 2013, The American journal of psychiatry.
[53] Y. Koshino,et al. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients , 2013, Neuropsychiatric disease and treatment.
[54] L. Rohde,et al. Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses , 2013, CNS Spectrums.
[55] R. Perera,et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. , 2013, The Cochrane database of systematic reviews.
[56] J. Brockmöller,et al. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.
[57] G. Hankins,et al. Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. , 2012, Journal of pharmaceutical and biomedical analysis.
[58] Y. de Koninck,et al. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile , 2012, Fundamental & clinical pharmacology.
[59] C. Andrade. Breast cancer and antidepressant use. , 2012, The Journal of clinical psychiatry.
[60] A. Quante,et al. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. , 2012, Journal of clinical psychopharmacology.
[61] M. Srisurapanont,et al. Bupropion for adults with attention‐deficit hyperactivity disorder: Meta‐analysis of randomized, placebo‐controlled trials , 2011, Psychiatry and clinical neurosciences.
[62] A. Pizon,et al. Bupropion Induced Serotonin Syndrome: A Case Report , 2010, Journal of Medical Toxicology.
[63] J. Wickens,et al. Neurobiology of ADHD , 2009, Neuropharmacology.
[64] S. Wonnacott,et al. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. , 2007, Biochemical pharmacology.
[65] J. Hughes. Depression during tobacco abstinence. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[66] R. Kast,et al. Bupropion: pharmacology and therapeutic applications , 2006, Expert review of neurotherapeutics.
[67] J. Jefferson,et al. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.
[68] M. Shoaib,et al. How does bupropion work as a smoking cessation aid? , 2005, Addiction biology.
[69] Brian T. O’Neill,et al. Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .
[70] R. Munhoz. Serotonin syndrome induced by a combination of bupropion and SSRIs. , 2004, Clinical neuropharmacology.
[71] G. Shepherd,et al. Intentional bupropion overdoses. , 2004, The Journal of emergency medicine.
[72] M. Bergström,et al. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography , 2003, Biological Psychiatry.
[73] J. Sasse,et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.
[74] L. Ferry,et al. EFFICACY AND SAFETY OF BUPROPION SR FOR SMOKING CESSATION: DATA FROM CLINICAL TRIALS AND FIVE YEARS OF POSTMARKETING EXPERIENCE , 2003, International journal of clinical practice.
[75] A. Metz,et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression , 2002, Biological Psychiatry.
[76] J. Avasarala,et al. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. , 2002, The Journal of emergency medicine.
[77] A. Buist,et al. Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation , 2001, Annals of Internal Medicine.
[78] C. Lindley,et al. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[79] Jean Logan,et al. Brain dopamine and obesity , 2001, The Lancet.
[80] M. Damaj,et al. Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.
[81] D. Greenblatt,et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[82] C. Lindley,et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[83] M. Gitlin,et al. Bupropion-tranylcypromine combination for treatment-refractory depression. , 2000, Journal of Clinical Psychiatry.
[84] G. Chiara,et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs , 1996, Nature.
[85] P. Wender,et al. Bupropion treatment of attention-deficit hyperactivity disorder in adults. , 1990, The American journal of psychiatry.
[86] N. Isoherranen,et al. In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation , 2017, Biochemical pharmacology.
[87] H. Aubin. Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation , 2012, Drugs.
[88] Sohita Dhillon,et al. Bupropion , 2012, Drugs.
[89] M. Beyens,et al. Serious Adverse Reactions of Bupropion for Smoking Cessation , 2008, Drug safety.
[90] Maurizio Fava,et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. , 2005, Primary care companion to the Journal of clinical psychiatry.
[91] Stephen M. Stahl,et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.
[92] D. H. Schroeder,et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects , 2004, European Journal of Clinical Pharmacology.
[93] E. A. Gardner. Effects of bupropion on weight in patients intolerant to previous antidepressants , 1984 .
[94] F. Soroko,et al. The pharmacologic basis for therapeutic interest in bupropion. , 1983, The Journal of clinical psychiatry.
[95] D. H. Schroeder. Metabolism and kinetics of bupropion. , 1983, The Journal of clinical psychiatry.